As Ranbaxy Founders Exit, Daiichi Sankyo Assumes Complete Control; New Management Expects To Resolve U.S. FDA Issue

MUMBAI - Less than one year after acquiring a 64 percent equity stake in India's Ranbaxy for $4.6 billion, Japanese drug maker Daiichi Sankyo has taken complete control of the company's management after reaching an "amicable" agreement on the exit of Malvinder Singh, the grandson of Ranbaxy's founder, and two other directors: Sunil Godhwani and Balinder Dhillon

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip